Two-hit hypothesis
The Knudson hypothesis, also known as the two-hit hypothesis, is the hypothesis that most tumor suppressor genes require both alleles to be inactivated, either through mutations or through epigenetic silencing, to cause a phenotypic change.[1] It was first formulated by Alfred G. Knudson in 1971[2] and led indirectly to the identification of tumor suppressor genes. Knudson won the 1998 Albert Lasker Clinical Medical Research Award for this work.
Knudson performed a statistical analysis on cases of retinoblastoma, a tumor of the retina that occurs both as an inherited disease and sporadically. He noted that inherited retinoblastoma occurs at a younger age than the sporadic disease. In addition, the children with inherited retinoblastoma often developed the tumor in both eyes, suggesting an underlying predisposition.
Knudson suggested that two "hits" to DNA were necessary to cause the cancer. In the children with inherited retinoblastoma, the first mutation in what later came to be identified as the RB1 gene, was inherited, the second one acquired. In non-inherited retinoblastoma, instead two mutations, or "hits", had to take place before a tumor could develop, explaining the later onset.
It was later found that carcinogenesis (the development of cancer) depended both on the mutation of proto-oncogenes (genes that stimulate cell proliferation) and on the inactivation of tumor suppressor genes, which are genes that keep proliferation in check. Knudson's hypothesis refers specifically, however, to the heterozygosity of tumor suppressor genes. An inactivation of both alleles is required, as a single functional tumor suppressor gene is usually sufficient. Some tumor suppressor genes have been found to be "dose-dependent" so that inhibition of one copy of the gene (either via genetic or epigenetic modification) may encourage a malignant phenotype, which is termed haploinsufficiency.[3]
Related ideas
[edit]Field cancerization may be an extended form of the Knudson hypothesis. This is the phenomenon of various primary tumors developing in one particular area of the body, suggesting that an earlier "hit" predisposed the whole area for cancer.[citation needed]
Announced in 2011, chromothripsis similarly involves multiple mutations, but asserts that they may all appear at once. This idea, affecting only 2–3% of cases of cancer, although up to 25% of bone cancers, involves the catastrophic shattering of a chromosome into tens or hundreds of pieces and then being patched back together incorrectly. This shattering, it is presumed, takes place when the chromosomes are compacted during normal cell division, but the trigger for the shattering is unknown. Under this model, cancer arises as the result of a single, isolated event, rather than the slow accumulation of multiple mutations.[4]
The exact function of some tumor suppressor genes is not currently known (e.g. MEN1, WT1),[5] but based on these genes following the Knudson "two-hit" hypothesis, they are strongly presumed to be suppressor genes.
References
[edit]- ^ Abeloff's Clinical Oncology. Niederhuber, John E.,, Armitage, James O., Doroshow, James H.,, Kastan, M. B. (Michael B.),, Tepper, Joel E.,, Preceded by: Abeloff, Martin D. (6th ed.). Philadelphia, PA. 2019. p. 218. ISBN 978-0-323-56815-9. OCLC 1089396489.
{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link) - ^ Knudson A (1971). "Mutation and cancer: statistical study of retinoblastoma". Proc Natl Acad Sci USA. 68 (4): 820–823. Bibcode:1971PNAS...68..820K. doi:10.1073/pnas.68.4.820. PMC 389051. PMID 5279523.
- ^ Fang, Yanan; Tsao, Cheng-Chung; Goodman, Barbara K.; Furumai, Ryohei; Tirado, Carlos A.; Abraham, Robert T.; Wang, Xiao-Fan (4 August 2004). "ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background". The EMBO Journal. 23 (15): 3164–3174. doi:10.1038/sj.emboj.7600315. ISSN 0261-4189. PMC 514932. PMID 15282542.
- ^ Stephens PJ, Greenman CD, Fu B, et al. (January 2011). "Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development". Cell. 144 (1): 27–40. doi:10.1016/j.cell.2010.11.055. PMC 3065307. PMID 21215367.
- ^ Kumar, Vinay; Abbas, Abul K.; Aster, Jon C. (5 September 2014). Robbins & Cotran Pathologic Basis of Disease. Elsevier Health Sciences. ISBN 9780323296359.